加载中
Pluri Inc., a biotechnology company established in 2001 and headquartered in Haifa, Israel, specializes in developing innovative placenta-derived cell therapies. Its core mission is to tackle a range of inflammatory conditions, muscle injuries, and hematological disorders. The company's therapeutic pipeline centers on placental expanded (PLX) cell technology. A key candidate, PLX-PAD, is in advanced clinical development, with ongoing Phase III trials for muscle recovery after hip fracture surgery, Phase II studies for acute respiratory distress syndrome associated with COVID-19, and Phase I/II trials for steroid-refractory Graft-versus-Host Disease. Additionally, Pluri is advancing PLX-R18, a treatment designed to aid in incomplete hematopoietic recovery following hematopoietic cell transplantation and to address acute radiation syndrome. The company rebranded to Pluri Inc. in July 2022, having previously operated as Pluristem Therapeutics Inc.
前收盘价
US$1.04
+US$0.05 · +5.05%
盘中时间采用ET。市场数据可能有所延迟。
Pluri Inc., a biotechnology company established in 2001 and headquartered in Haifa, Israel, specializes in developing innovative placenta-derived cell therapies. Its core mission is to tackle a range of inflammatory conditions, muscle injuries, and hematological disorders. The company's therapeutic pipeline centers on placental expanded (PLX) cell technology. A key candidate, PLX-PAD, is in advanced clinical development, with ongoing Phase III trials for muscle recovery after hip fracture surgery, Phase II studies for acute respiratory distress syndrome associated with COVID-19, and Phase I/II trials for steroid-refractory Graft-versus-Host Disease. Additionally, Pluri is advancing PLX-R18, a treatment designed to aid in incomplete hematopoietic recovery following hematopoietic cell transplantation and to address acute radiation syndrome. The company rebranded to Pluri Inc. in July 2022, having previously operated as Pluristem Therapeutics Inc.
日内区间
当前US$1.04
52周区间
当前US$1.04
盘中时间采用ET。市场数据可能有所延迟。
Pluri Inc., a biotechnology company established in 2001 and headquartered in Haifa, Israel, specializes in developing innovative placenta-derived cell therapies. Its core mission is to tackle a range of inflammatory conditions, muscle injuries, and hematological disorders. The company's therapeutic pipeline centers on placental expanded (PLX) cell technology. A key candidate, PLX-PAD, is in advanced clinical development, with ongoing Phase III trials for muscle recovery after hip fracture surgery, Phase II studies for acute respiratory distress syndrome associated with COVID-19, and Phase I/II trials for steroid-refractory Graft-versus-Host Disease. Additionally, Pluri is advancing PLX-R18, a treatment designed to aid in incomplete hematopoietic recovery following hematopoietic cell transplantation and to address acute radiation syndrome. The company rebranded to Pluri Inc. in July 2022, having previously operated as Pluristem Therapeutics Inc.
日内区间
当前US$1.04
52周区间
当前US$1.04
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2026财年 | 2025财年 | 2024财年 | 2023财年 | 2022财年 |
|---|---|---|---|---|---|
| 营收 | 101.6万 USD | 133.6万 USD | 32.6万 USD | 28.7万 USD | 23.4万 USD |
| 销货成本 | 56.3万 USD | 68.2万 USD | 4000 USD | 9000 USD | 105.3万 USD |
| 毛利 | 45.3万 USD | 65.4万 USD | 32.2万 USD | 27.8万 USD | −81.9万 USD |
| 研究与开发 | 1530.6万 USD | 1285.1万 USD | 1244.6万 USD | 1574.5万 USD | 2437.7万 USD |
| 销售、一般及管理费用 | 1029.9万 USD | 997.9万 USD | 1003.4万 USD | 1177.9万 USD | 1745万 USD |
| 营业费用 | 2539.1万 USD | 2283万 USD | 2248万 USD | 2752.4万 USD | 4077.4万 USD |
| 利息收入 | 48.8万 USD | 114.4万 USD | 131.4万 USD | 108.4万 USD | 58.1万 USD |
| 利息支出 | −93.2万 USD | 87.3万 USD | 86.6万 USD | 84.3万 USD | 88.7万 USD |
| 折旧和摊销 | 51.1万 USD | 31.6万 USD | 25.3万 USD | 36.2万 USD | 105.3万 USD |
| 营业利润 | −2493.8万 USD | −2217.6万 USD | −2215.8万 USD | −2724.6万 USD | −4159.3万 USD |
| 净利润 | −2382.1万 USD | −2258.3万 USD | −2088.8万 USD | −2832.1万 USD | −4124.2万 USD |
公司数据更新于 2026年10月8日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$12.00
上涨空间 1053.85%| 行动 | 生效日期 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股票拆分 | 2024年4月1日 | 1:8 | — | — |
股票拆分 | 2019年7月25日 | 1:10 | — | — |
股票拆分 | 2007年11月26日 | 1:200 | — | — |
已生效 2024年4月1日
1:8
已生效 2019年7月25日
1:10
已生效 2007年11月26日
1:200
报告持有此股票敞口的交易所交易基金。
AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
